Physician profile
Wassim Atassi
NPI 1871533927
$1,561.50
in general payments reported to CMS, 2019-2025
24 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $176 · 2021: $310 · 2022: $280 · 2023: $142 · 2024: $161 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.87 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $325.04 | 2021-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.81 | 2019-2021 | |
| Novo Nordisk INC | $118.98 | 2019-2025 | |
| Lilly USA, LLC | $118.64 | 2019-2025 | Zepbound, Mounjaro |
| Intuitive Surgical, INC. | $112.24 | 2025 | |
| Abbvie INC. | $93.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $81.01 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $77.90 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $64.88 | 2023-2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $58.87 | 2020-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.00 | 2021-2022 | |
| Advanced Respiratory, INC | $31.35 | 2021 | |
| Mylan Specialty L.P. | $30.85 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.14 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.23 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $19.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.01 | 2024 | |
| United Therapeutics Corporation | $17.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.45 | 2024 | Quviviq |
| Abbott Laboratories | $15.14 | 2024 | Proclaim |
| Sunovion Pharmaceuticals INC. | $14.05 | 2020 | |
| Dexcom, INC. | $13.25 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $7.34 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wassim Atassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.